Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Design and characterization of an organogel system containing ascorbic acid microparticles produced with propolis by-product.

de Francisco LMB, Pinto D, Rosseto HC, de Toledo LAS, Dos Santos RS, Costa PJCD, Oliveira MBPP, Sarmento B, Rodrigues F, Bruschi ML.

Pharm Dev Technol. 2019 Oct 3:1-14. doi: 10.1080/10837450.2019.1669643. [Epub ahead of print]

PMID:
31535923
2.

Biomedical Platform Development of a Chlorophyll-Based Extract for Topic Photodynamic Therapy: Mechanical and Spectroscopic Properties.

Campanholi KDSS, Braga G, da Silva JB, da Rocha NL, de Francisco LMB, de Oliveira ÉL, Bruschi ML, de Castro-Hoshino LV, Sato F, Hioka N, Caetano W.

Langmuir. 2018 Oct 30;34(43):13077. doi: 10.1021/acs.langmuir.8b02961. Epub 2018 Oct 18. No abstract available.

PMID:
30335397
3.

Correction: Development of a microparticulate system containing Brazilian propolis by-product and gelatine for ascorbic acid delivery: evaluation of intestinal cell viability and radical scavenging activity.

de Francisco LMB, Pinto D, Rosseto HC, de Toledo LAS, Dos Santos RS, Costa P, Rodrigues F, Oliveira MBPP, Sarmento B, Bruschi ML.

Food Funct. 2018 Aug 15;9(8):4518. doi: 10.1039/c8fo90034e.

PMID:
30019728
4.

Development of a microparticulate system containing Brazilian propolis by-product and gelatine for ascorbic acid delivery: evaluation of intestinal cell viability and radical scavenging activity.

de Francisco LMB, Pinto D, Rosseto HC, de Toledo LAS, Dos Santos RS, Costa P, Rodrigues F, Oliveira MBPP, Sarmento B, Bruschi ML.

Food Funct. 2018 Aug 15;9(8):4194-4206. doi: 10.1039/c8fo00863a. Erratum in: Food Funct. 2018 Jul 18;:.

PMID:
29993073
5.

Biomedical Platform Development of a Chlorophyll-Based Extract for Topic Photodynamic Therapy: Mechanical and Spectroscopic Properties.

Campanholi KDSS, Braga G, da Silva JB, da Rocha NL, de Francisco LMB, de Oliveira ÉL, Bruschi ML, de Castro-Hoshino LV, Sato F, Hioka N, Caetano W.

Langmuir. 2018 Jul 17;34(28):8230-8244. doi: 10.1021/acs.langmuir.8b00658. Epub 2018 Jul 6. Erratum in: Langmuir. 2018 Oct 30;34(43):13077.

PMID:
29933698
6.

Nanostructured lipid systems modified with waste material of propolis for wound healing: Design, in vitro and in vivo evaluation.

Rosseto HC, Toledo LAS, Francisco LMB, Esposito E, Lim Y, Valacchi G, Cortesi R, Bruschi ML.

Colloids Surf B Biointerfaces. 2017 Oct 1;158:441-452. doi: 10.1016/j.colsurfb.2017.07.029. Epub 2017 Jul 10.

PMID:
28728086
7.

Formulation and Evaluation of a Mucoadhesive Thermoresponsive System Containing Brazilian Green Propolis for the Treatment of Lesions Caused by Herpes Simplex Type I.

Mazia RS, de Araújo Pereira RR, de Francisco LM, Natali MR, Dias Filho BP, Nakamura CV, Bruschi ML, Ueda-Nakamura T.

J Pharm Sci. 2016 Jan;105(1):113-21. doi: 10.1016/j.xphs.2015.11.016. Epub 2016 Jan 13.

PMID:
26852846
8.

The Use of Propolis in Micro/Nanostructured Pharmaceutical Formulations.

Bruschi ML, de A Pereira RR, de Francisco LM.

Recent Pat Drug Deliv Formul. 2016;10(2):130-40. Review.

PMID:
26715146
9.

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.

Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, Mautino MR, Celis E, Sharpe AH, Francisco LM, Powell JD, Yagita H, Mellor AL, Blazar BR, Munn DH.

Sci Adv. 2015 Nov 6;1(10):e1500845. doi: 10.1126/sciadv.1500845. eCollection 2015 Nov.

10.

A high performance liquid chromatography with ultraviolet method for Eschweilera nana leaves and their anti-inflammatory and antioxidant activities.

Outuki PM, Lazzeri NS, de Francisco LM, Bersani-Amado CA, Ferreira IC, Cardoso ML.

Pharmacogn Mag. 2015 Jul-Sep;11(43):619-26. doi: 10.4103/0973-1296.160464.

11.

An overview of recent patents on composition of mucoadhesive drug delivery systems.

Bruschi ML, de Francisco LM, S de Toledo Lde A, Borghi FB.

Recent Pat Drug Deliv Formul. 2015;9(1):79-87. Review.

PMID:
25420876
12.

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance.

Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco LM, Hua P, Duke-Cohan JS, Umetsu DT, Sharpe AH, DeKruyff RH, Freeman GJ.

J Exp Med. 2014 May 5;211(5):943-59. doi: 10.1084/jem.20130790. Epub 2014 Apr 21.

13.

The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood.

Sage PT, Francisco LM, Carman CV, Sharpe AH.

Nat Immunol. 2013 Feb;14(2):152-61. doi: 10.1038/ni.2496. Epub 2012 Dec 16.

14.

Development and characterization of gelatin and ethylcellulose microparticles designed as platforms to delivery fluoride.

de Francisco LM, Cerquetani JA, Bruschi ML.

Drug Dev Ind Pharm. 2013 Nov;39(11):1644-50. doi: 10.3109/03639045.2012.728610. Epub 2012 Oct 4.

PMID:
23034061
15.

Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1.

Hirahara K, Ghoreschi K, Yang XP, Takahashi H, Laurence A, Vahedi G, Sciumè G, Hall AO, Dupont CD, Francisco LM, Chen Q, Tanaka M, Kanno Y, Sun HW, Sharpe AH, Hunter CA, O'Shea JJ.

Immunity. 2012 Jun 29;36(6):1017-30. doi: 10.1016/j.immuni.2012.03.024. Epub 2012 Jun 21.

16.

Neuronal programmed cell death-1 ligand expression regulates retinal ganglion cell number in neonatal and adult mice.

Sham CW, Chan AM, Kwong JM, Caprioli J, Nusinowitz S, Chen B, Lee JG, Gandhi NM, Francisco LM, Sharpe AH, Chen L, Braun J, Gordon LK.

J Neuroophthalmol. 2012 Sep;32(3):227-37.

17.

Proposal for an integrative methodology to development the ergonomic program.

Francisco LM, De la Vega E, Lucero Duarte K, Diaz Muro M.

Work. 2012;41 Suppl 1:5772-4. doi: 10.3233/WOR-2012-0947-5772.

PMID:
22317683
18.

Study about upper limb on highly repetitive work in maquila operations.

Francisco LM, De la Vega E, Rodriguez M, Ayala A.

Work. 2012;41 Suppl 1:5621-3. doi: 10.3233/WOR-2012-0897-5621.

PMID:
22317630
19.

Physiologic control of IDO competence in splenic dendritic cells.

Baban B, Chandler PR, Johnson BA 3rd, Huang L, Li M, Sharpe ML, Francisco LM, Sharpe AH, Blazar BR, Munn DH, Mellor AL.

J Immunol. 2011 Sep 1;187(5):2329-35. doi: 10.4049/jimmunol.1100276. Epub 2011 Aug 3.

20.

The PD-1 pathway in tolerance and autoimmunity.

Francisco LM, Sage PT, Sharpe AH.

Immunol Rev. 2010 Jul;236:219-42. doi: 10.1111/j.1600-065X.2010.00923.x. Review.

21.

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.

Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH.

J Exp Med. 2009 Dec 21;206(13):3015-29. doi: 10.1084/jem.20090847. Epub 2009 Dec 14.

22.

B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function.

Ruffner MA, Kim SH, Bianco NR, Francisco LM, Sharpe AH, Robbins PD.

Eur J Immunol. 2009 Nov;39(11):3084-90. doi: 10.1002/eji.200939407.

23.

Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells.

Chen L, Sham CW, Chan AM, Francisco LM, Wu Y, Mareninov S, Sharpe AH, Freeman GJ, Yang XJ, Braun J, Gordon LK.

Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4941-8. doi: 10.1167/iovs.09-3602. Epub 2009 May 6.

24.

PD-1 and its ligands in T-cell immunity.

Keir ME, Francisco LM, Sharpe AH.

Curr Opin Immunol. 2007 Jun;19(3):309-14. Epub 2007 Apr 12. Review.

PMID:
17433872
25.

Tumor-specific killer cells in paraneoplastic cerebellar degeneration.

Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB.

Nat Med. 1998 Nov;4(11):1321-4.

PMID:
9809559
26.

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes.

Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N.

J Exp Med. 1998 Oct 5;188(7):1359-68.

Supplemental Content

Loading ...
Support Center